Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-01

Clinical Trial Update: A Study of TAK-861 for the Treatment of Narcolepsy Type 1 [Phase 3]

View source ↗

Summary

The Phase 3 trial of TAK-861 for Narcolepsy Type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAK-861

Snippet

Sponsor: Takeda | Conditions: Narcolepsy Type 1 | Phase 3 | Status: COMPLETED